We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Johnson & Johnson stands second among the most ...

Johnson & Johnson eyes FDA nod to icotrokinra after phase III studies show strong skin clearance and safety in plaque ...

Biopharma giant Johnson & Johnson’s ($JNJ) stock hit new highs this year after reporting its Q2 results on July 16th, giving ...

AstraZeneca Plc (NASDAQ:AZN) on Thursday reported high-level results from the PREVAIL Phase 3 trial evaluating the safety and ...

US President Trump imposed 200% tariff on pharmaceuticals affecting US drug prices and supply chain, but analysts say it may ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

As a baseline, the chance that JNJ will rise over any given week is 54.84%. Therefore, the statistical response to the 6-4-D sequence raises the odds considerably for the bullish speculator.

Stock futures dipped early Wednesday as traders awaited fresh inflation data and President Trump's latest tariff ...

The U.S. drug regulator said on Friday a unit of Johnson & Johnson issued a correction for certain lots of a part related to ...

Johnson & Johnson (JNJ) stock in focus as Darzalex SC developed with Halozyme (HALO) and Genmab (GMAB) receives EU nod for ...

Icotrokinra is designed to selectively block the IL-23 receptor, which drives inflammation in plaque psoriasis and ...

Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has received approval from the European Commission (EC) ...